 This is a randomized, multicenter, parallel-group, open-label study comparing the tolerability of Rebif injections 44 microgram mcg administered subcutaneously three times a week with and without RebijectTMMini, an auto-injection device in relapsing-remitting multiple sclerosis MS subjects. Subjects will be randomly assigned to either one of the two Rebif groups in a 1:1 ratio on Study Day 1 stratified by center. Subjects will receive a minimum of 3 months of treatment with Rebif 44 mcg three times a week and will be asked to assess their injection site reactions on a weekly basis. Clinic visit will occur at 1 and 3 months after the initiation of treatment. 